<DOC>
	<DOCNO>NCT02631031</DOCNO>
	<brief_summary>The choice drug administration time may affect pharmacokinetics and/or drug response , knowledge circadian rhythm-dependent effect may help reduce side effect enhance efficacy . This study design investigate potential influence time drug administration pharmacokinetics pharmacodynamics valsartan healthy subject .</brief_summary>
	<brief_title>Chronopharmacology Valsartan Normotensive Subjects</brief_title>
	<detailed_description>International guideline recommend use long acting , once-daily medication provide 24h efficacy ; improve adherence therapy minimize BP variability smoother consistent BP control . Valsartan approve used once-daily , without specification treatment-time package insert . Several trial investigate differential effect morning versus even administration valsartan hypertensive patient , however , result study contradict . Furthermore , specific administration time dependent dose response curve previously investigate . So , study design investigate potential influence time drug administration pharmacokinetics pharmacodynamics valsartan healthy subject .</detailed_description>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . At least 18 year old 45 healthy male volunteer 2 . Actual weight Â± 30 % ideal body weight base sex , height , body frame 3. Who pass screen parameter include physical examination , laboratory test . 4. Who able communicate effectively study personnel , literate , able give consent . 5. diurnal active subject eight hour night sleep . 6. free drug exposure know interfere pharmacokinetics/pharmacodynamics assay valsartan least 10 day prior study 1 . Treatment known enzymeinducing/inhibiting agent within 30 day prior start study throughout study . 2 . Susceptibility allergic reaction valsartan . 3 . Any prior surgery gastrointestinal tract may interfere drug absorption . 4 . Gastrointestinal disease . 5 . Renal disease . 6 . Cardiovascular disease . 7 . Pancreatic disease include diabetes . 8 . Hepatic disease . 9 . Hematological disease pulmonary disease 10 . Abnormal laboratory value . 11 . Subjects donate blood involve multiple dose study require large volume blood ( 500 ml ) drawn within 6 week precede start study . 12 . Nocturnal active subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Chronokinetics</keyword>
	<keyword>chronodynamics</keyword>
	<keyword>chronopharmacology</keyword>
	<keyword>valsartan</keyword>
</DOC>